Table 1.
Clinical outcomes of repeated IPC with systemic chemotherapy for gastric cancer with PM.
| Author, Year | IP Regimen | Systemic Regimen | Study | n | MST (mo) | 1 y OS (%) | Cytology Negative Conversion Rate (%) |
|---|---|---|---|---|---|---|---|
| Ishigami, 2010 [33] | PTX (20 mg/m2) | S-1 + PTX | P2 | 40 | 22.5 | 78 | 86 |
| Fujiwara, 2012 [34] | DTX (40~60 mg/m2) | S-1 | R/S | 18 | 24.6 | 76 | 78 |
| Fushida, 2013 [35] | DTX (45 mg/m2) | S-1 | P1/2 | 39 | 16.2 | 70.4 | 81 |
| Yamaguchi, 2013 [36] | PTX (20 mg/m2) | S-1 + PTX | P1 | 35 | 17.6 | 77.1 | 97 |
| Ishigami, 2016 [37] | PTX (20 mg/m2) | S-1 + PTX | P3 | 114 | 17.7 | 71.9 | 95 |
| Fujiwara, 2016 [38] | PTX (40 mg/m2) | S-1 + L-OHP | P2 | 60 | NR | 71.5 | 71 |
| Fukushima, 2017 [39] | DTX (10 mg/m2) | Cap + CDDP | P2 | 48 | NR | 75 | 76 |
| Cho, 2017 [40] | DTX (100 mg/m2) | Cap + CDDP | P1/2 | 39 | 15.1 | - | - |
| Shinkai, 2018 [41] | PTX (60 mg/m2) | S-1 + PTX + CDDP | P2 | 17 | 23.9 | 82.4 | - |
| Yonemura, 2020 [42] | DTX (30 mg/m2) + CDDP (30 mg/m2) | DTX + CDDP | R/S | 419 | 20.5 | 70 | 63.5 |
| Saito, 2021 [43] | PTX (40 mg/m2) | S-1 + L-OHP | R/S | 44 | 25.8 | 79.5 | 86 |
Cap—capecitabine; CDDP—cisplatin; DTX—docetaxel; IPC—intraperitoneal chemotherapy; L-OHP—oxaliplatin; MST—median survival time; NR—not reached; OS—overall survival; PM—peritoneal metastases; PTX—paclitaxel; P1, 2, 3—phase I, II, III; R/S—retrospective study; -—not described.